Reversal of P-glycoprotein-Mediated Multidrug Resistance in Human Leukemia Cell Line K562/A02 by Archangelicin

Chinese Journal of Natural Medicines

Volumn 9, Issue 2, 2011, Pages 146-150

  Wang, Shu Qi ^a   Li, Xia ^a,b   Wang, Xiao Ning ^a   Lou, Hong Xiang ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Archangelicin; K562 A02 cells; Multidrug resistance; P glycoprotein

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ARCHANGELICIN; DOXORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; PLANT EXTRACT; RHODAMINE 123; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 79956296911     PISSN: 20956975     EISSN: 18755364     Source Type: Journal    
DOI: 10.3724/SP.J.1009.2011.00146     Document Type: Article

References (14)

1. Schmidt M, Ungvari J, Glode J, et al. New 1, 3-dioxolane and 1, 3-dioxane derivatives as effective modulators to overcome multidrug resistance [J]. Bioorg Med Chem 2007, 15(6):2283-2297.
2. Tiwari AK, Sodani K, Wang SR, et al. Nilotinib (AMN107, Tasigna (R)) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters [J]. Biochem Pharmacol 2009, 78(2):153-161.
3. Zhu HJ, Wang JS, Guo QL, et al. Reversal of p-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6 [J]. Biol Pharm Bull 2005, 28(10):1974-1978.
4. Avendano C, Menendez JC Inhibitors of multidrug resistance to antitumor agents (MDR) [J]. Curr Med Chem 2002, 9(2):159-193.
5. Wesierska-Gadek J Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly (ADP-ribose) polymerase-1 knock-out cells to doxorubicin action [J]. J Cell Biochem 2005, 95(5):1012-1028.
6. Ullah MF Cancer multidrug resistance (MDR): A major impediment to effective chemotherapy [J]. Asian Pac J Cancer Prevent 2008, 9(1):1-6.
7. Sun B, Yuan HQ, Xi GM, et al. Synthesis and multidrug resistance reversal activity of dihydroptychantol A and its novel derivatives [J]. Bioorg Med Chem 2009, 17(14):4981-4989.
8. Li X, Sun B, Zhu CJ, et al. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells [J]. Toxicol in Vitro 2009, 23(1):29-36.
9. Ji BS, He L CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells [J]. J Pharm Pharmacol 2007, 59(7):1011-1015.
10. Zhu B, Liu GT, Zhao YM, et al. Chemosensitizing multiple drug resistance of human carcinoma by Bicyclol involves attenuated p-glycoprotein, GST-P and Bcl-2 [J]. Cancer Biol Ther 2006, 5(5):536-543.
11. Ji BS, He L, Liu GQ Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells [J]. Life Sci 2005, 77(18):2221-2232.
12. Kim YK, Song YJ, Seo DW, et al. Reversal of multidrug resistance by 4-chloro-N-(3-((E)-3-(4-hydroxy-3-methoxy-phenyl) acryloyl) phenyl) benzamide through the reversible inhibition of P-glycoprotein [J]. Biochem Biophys Res Commun 2007, 355(1):136-142.
13. Xu D, Lu Q, Hu X Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol [J]. Cancer Lett 2006, 243(2):274-280.
14. Wu JY, Fong WF, Zhang JX, et al. Reversal of multidrug resistance in cancer cells by pyranocoumarins isolated from Radix Peucedani [J]. Euro J Pharmacol 2003, 473(1):9-17.